These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35246604)

  • 1. Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication.
    Moretti S; Abdel-Aziz AK; Ceccacci E; Pallavicini I; Santoro F; de Thé H; Minucci S
    Leukemia; 2022 May; 36(5):1306-1312. PubMed ID: 35246604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
    Leiva M; Moretti S; Soilihi H; Pallavicini I; Peres L; Mercurio C; Dal Zuffo R; Minucci S; de Thé H
    Leukemia; 2012 Jul; 26(7):1630-7. PubMed ID: 22333881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
    Ohnishi K
    Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
    Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
    Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.
    Jiao B; Ren ZH; Liu P; Chen LJ; Shi JY; Dong Y; Ablain J; Shi L; Gao L; Hu JP; Ren RB; de Thé H; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3495-500. PubMed ID: 23382200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392.
    De Bellis F; Carafa V; Conte M; Rotili D; Petraglia F; Matarese F; Françoijs KJ; Ablain J; Valente S; Castellano R; Goubard A; Collette Y; Mandoli A; Martens JH; de Thé H; Nebbioso A; Mai A; Stunnenberg HG; Altucci L
    Cancer Res; 2014 Apr; 74(8):2328-39. PubMed ID: 24566867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
    Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
    Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells.
    Hennig D; Müller S; Wichmann C; Drube S; Pietschmann K; Pelzl L; Grez M; Bug G; Heinzel T; Krämer OH
    Br J Cancer; 2015 Jan; 112(2):329-37. PubMed ID: 25514379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
    Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
    Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R; de Thé H
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y
    Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription therapy for acute promyelocytic leukaemia.
    Douer D
    Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
    Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the histone deacetylase complex in acute promyelocytic leukaemia.
    Lin RJ; Nagy L; Inoue S; Shao W; Miller WH; Evans RM
    Nature; 1998 Feb; 391(6669):811-4. PubMed ID: 9486654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
    Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
    Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.